ArticleResearch square2025
Antibacterial Silver Modified Gallium Metal-Organic Frameworks for Odontogenic Infections.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
Abstract
Surgical debridement of infected oral tissues can compromise maxillofacial aesthetics and anatomical function, thereby reinforcing the use of antibiotics as a first-line therapy. However, the escalating threat of multidrug-resistant pathogens has intensified the need for non-antibiotic alternatives that can be applied topically and eliminate microbes regardless of their resistance profiles. In this study, we introduce hybrid gallium-silver metal-organic frameworks (MOFs) as a novel therapeutic platform that integrates gallium-mediated disruption of iron-dependent metabolic pathways with the biophysical antimicrobial effects of silver nanoparticles, resulting in potent and rapid inhibition of oral streptococcal growth. Using complementary spectroscopic and microscopic techniques, we elucidate the structure and physicochemical properties of these gallium-silver MOFs, leveraging these insights to understand their antibacterial mechanisms. Cytotoxicity assays conducted on human osteogenic cells help define an appropriate therapeutic window. These proof-of-concept findings suggest that, with further optimization, gallium-silver MOFs hold promise as an attractive topical antimicrobial with potential to rapidly clear odontogenic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.